A 29-year-old woman is evaluated in the clinic as a new patient. She has no complaints and reports feeling well. She exercises regularly, follows a balanced diet, and takes no medications or supplements. Her father has a history of asymptomatic hypercalcemia that has never required medical treatment. Vital signs are within normal limits. Physical examination is unremarkable.
Laboratory studies show:
| Test | Result | Reference Range |
|---|---|---|
| Serum calcium | mg/dL | mg/dL |
| Serum albumin | g/dL | g/dL |
| Serum phosphorus | mg/dL | mg/dL |
| Serum creatinine | mg/dL | mg/dL |
| Intact parathyroid hormone | pg/mL | pg/mL |
A 24-hour urine collection yields:
| Test | Result | Reference Range |
|---|---|---|
| Urine calcium | mg/24 hr | mg/24 hr |
| Urine creatinine | mg/24 hr | mg/24 hr |
Which of the following is the most appropriate next step in management?
- Reassurance and clinical observationAnswer
- BReferral for parathyroidectomy
- CSestamibi parathyroid scintigraphy
- DDual-energy x-ray absorptiometry
- EMeasurement of serum 1,25-dihydroxyvitamin D
Answer
Reassurance and clinical observation
The correct approach is reassurance and clinical observation. This patient presents with asymptomatic hypercalcemia and an intact parathyroid hormone (PTH) level that is mildly elevated, indicating a PTH-dependent etiology. The critical distinguishing factor is the very low 24-hour urine calcium ( mg/24 hr) in the setting of hypercalcemia.
To formally differentiate between the two most likely causes—primary hyperparathyroidism and familial hypocalciuric hypercalcemia (FHH)—the calcium-creatinine clearance ratio (CCCR) must be calculated:
A CCCR of is highly sensitive and specific for FHH, whereas primary hyperparathyroidism typically yields a CCCR . Furthermore, the patient's family history of asymptomatic, untreated hypercalcemia strongly supports this autosomal dominant condition. FHH is caused by an inactivating mutation of the calcium-sensing receptor (CaSR) in the parathyroid glands and kidneys, requiring higher calcium levels to suppress PTH and increasing renal calcium reabsorption. It is a benign condition that does not cause progressive bone loss or renal stones; therefore, medical or surgical interventions are not indicated, and the best step is reassurance.
To formally differentiate between the two most likely causes—primary hyperparathyroidism and familial hypocalciuric hypercalcemia (FHH)—the calcium-creatinine clearance ratio (CCCR) must be calculated:
A CCCR of is highly sensitive and specific for FHH, whereas primary hyperparathyroidism typically yields a CCCR . Furthermore, the patient's family history of asymptomatic, untreated hypercalcemia strongly supports this autosomal dominant condition. FHH is caused by an inactivating mutation of the calcium-sensing receptor (CaSR) in the parathyroid glands and kidneys, requiring higher calcium levels to suppress PTH and increasing renal calcium reabsorption. It is a benign condition that does not cause progressive bone loss or renal stones; therefore, medical or surgical interventions are not indicated, and the best step is reassurance.
Step-by-Step Solution
Key Concept
Familial hypocalciuric hypercalcemia (FHH) presents with PTH-dependent hypercalcemia but is distinguished from primary hyperparathyroidism by a very low 24-hour urine calcium and a calcium-creatinine clearance ratio (CCCR) of . It is a benign condition that requires only reassurance and observation.